Established Market Leader BioFire Diagnostics has over 25 years of experience in molecular diagnostics, with a strong reputation for comprehensive syndromic infectious disease testing and FDA-cleared assays for a wide range of pathogens, positioning it as a trusted provider for hospital and laboratory buyers seeking reliable, rapid diagnostic solutions.

Innovative Product Portfolio The BioFire FilmArray System offers the easiest, fastest, and most comprehensive multiplex PCR testing available, including panels for respiratory, bloodstream, and other infectious diseases. This innovation creates sales opportunities with hospitals, pathology labs, and public health agencies aiming for quick, definitive diagnosis.

Recent Regulatory Milestones BioFire’s recent Emergency Use Authorization for the BioFire RP2.1 panel, including SARS-CoV-2 detection, highlights demand for COVID-19 diagnostics and presents opportunities to supply healthcare providers across government, hospital, and urgent care sectors expanding testing capacity.

Growing Revenue Base With a revenue between $100 million and $250 million, BioFire is a lucrative target for sales of complementary reagents, software upgrades, and service contracts to its expanding customer base of clinical laboratories, hospitals, and research institutions worldwide.